Monte Rosa Therapeutics (GLUE) EBIAT: 2023-2025
Historic EBIAT for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Sep 2025 value amounting to -$27.1 million.
- Monte Rosa Therapeutics' EBIAT fell 13.50% to -$27.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.9 million, marking a year-over-year increase of 117.54%. This contributed to the annual value of -$72.7 million for FY2024, which is 46.31% up from last year.
- Per Monte Rosa Therapeutics' latest filing, its EBIAT stood at -$27.1 million for Q3 2025, which was down 120.26% from -$12.3 million recorded in Q2 2025.
- Over the past 5 years, Monte Rosa Therapeutics' EBIAT peaked at $46.9 million during Q1 2025, and registered a low of -$35.2 million during Q2 2023.
- Its 3-year average for EBIAT is -$18.2 million, with a median of -$30.3 million in 2024.
- Data for Monte Rosa Therapeutics' EBIAT shows a peak YoY increase of 246.66% (in 2025) and a maximum YoY decrease of 13.50% (in 2025) over the last 5 years.
- Monte Rosa Therapeutics' EBIAT (Quarterly) stood at -$33.3 million in 2023, then surged by 140.35% to $13.4 million in 2024, then dropped by 13.50% to -$27.1 million in 2025.
- Its EBIAT stands at -$27.1 million for Q3 2025, versus -$12.3 million for Q2 2025 and $46.9 million for Q1 2025.